Search

Your search keyword '"Dillon, Christopher A"' showing total 469 results

Search Constraints

Start Over You searched for: Author "Dillon, Christopher A" Remove constraint Author: "Dillon, Christopher A"
469 results on '"Dillon, Christopher A"'

Search Results

1. Observations and modelling of intensity timeseries for biomedical and astrophysical applications

2. Treatment of apathy in Parkinson's disease: A bayesian network meta-analysis of randomised controlled trials

4. The prevalence of postacute sequelae of coronavirus disease 2019 in solid organ transplant recipients: Evaluation of risk in the National COVID Cohort Collaborative

5. Statistical Signatures of Nanoflare Activity. II. A Nanoflare Explanation for Periodic Brightenings in Flare Stars observed by NGTS

6. Nonelective coronary artery bypass graft outcomes are adversely impacted by Coronavirus disease 2019 infection, but not altered processes of care: A National COVID Cohort Collaborative and National Surgery Quality Improvement Program analysis

7. Hormone replacement therapy and COVID-19 outcomes in solid organ transplant recipients compared with the general population

8. Risk of severe acute respiratory syndrome coronavirus 2 infection among women with polycystic ovary syndrome

9. COVID-19 outcomes in persons with hemophilia: results from a US-based national COVID-19 surveillance registry

10. Thirty-Day Mortality and Complication Rates in Total Joint Arthroplasty After a Recent COVID-19 Diagnosis: A Retrospective Cohort in the National COVID Cohort Collaborative (N3C)

11. The Prevalence of Post-Acute Sequelae of COVID-19 in Solid Organ Transplant Recipients: Evaluation of Risk in the National COVID Cohort Collaborative (N3C)

13. Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space.

16. Risk for stillbirth among pregnant individuals with SARS-CoV-2 infection varied by gestational age

19. Nonelective coronary artery bypass graft outcomes are adversely impacted by Coronavirus disease 2019 infection, but not altered processes of care: A National COVID Cohort Collaborative and National Surgery Quality Improvement Program analysis

22. Figure S6 from Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody

23. Table S1, Table S3, Figures S1-S8 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy

24. Data from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

25. Supplementary Figures from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

26. Data from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy

27. Supplementary Data S2 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

28. Supplementary Methods from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy

29. Supplementary Methods from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

30. Table S2 from Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy

31. Hormone Replacement Therapy and COVID-19 Outcomes in Solid Organ Transplant Recipients Compared with the General Population

39. 1367 A highly-selective HPK1 inhibitor enhances T cell receptor signaling and T cell activation potential, increasing antigen recognition and efficacy of PD-1 therapy

46. Calcaneal lipofibromatosis reconstructed with reverse sural artery flap: A case report

49. SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

Catalog

Books, media, physical & digital resources